A Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor for use in the treatment or prevention of a disease in a subject, wherein the disease is a pathological or deregulated immune response caused as a side effect by a treatment of the subject with an Inhibitor of κB (IκB) Kinase (IKK)/Nuclear Factor κB (NFxB) - signaling inhibitor, wherein the RIPK1 inhibitor and the IKK/NFxB signaling inhibitor are selected from a small molecule, an antigen binding protein (ABP), an antisense or inhibitory DNA or RNA, a ribozyme, an RNA or DNA aptamer, RNAi, siRNA, shRNA, a genetic construct for targeted gene editing, such as a CRISPR/Cas9 construct and/or a guide nucleic acid (gRNA or gDNA) and/or tracrRNA; wherein, (i) when the RIPK1 inhibitor is a small molecule, the RIPK1 inhibitor is selected from GSK2982772, necrostatin-1 (5-(1H-indo1-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone, 5-(indoi-3-ylmethyl)-3-methyl-2-thio-hydantoin) and necrostatin-1 stable (5-((7-chloro-1 H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 5-((7-chloro-1H-indo1-3-yl)methyl)-3-methylimidazolidine-2,4-dione); or (ii) when the IKK/NFxB signaling inhibitor is a small molecule, the IKK/NFxB signaling inhibitor is selected from SPC839, Anilino-Pyrimidine Derivative, MLN120B or PS1145, BMS- 34554 1*, IKK inhibitor III, SC- 514*, Amino-imidazolecarboxamide derivative, Ureudothiophenecarboxamide derivatives, Diarylpybidine derivative, Pyridooxazinone derivative, Indolecarboxamide derivative, Benzoimidazole carboxamide derivative, Pyrazolo[4,3-c]quinoline derivative, Imidazolylquinoline-carbxaldehyde semicarbazide derivative, Pyridyl Cyanoguanidine derivate, IkB Kinase Inhibitor Peptide, IKK-2 Inhibitor IV [5-(p- Fluorophenyl)-2-ureido]thiophene-3-carboxamide, IKK Inhibitor II, Wedelolactone, IKK Inhibitor VII, IKK-2 Inhibitor V N-(3,5-Bis- trifluoromethylphenyl)-5-chloro-2-hydroxybenzamide IMD-0354, IKK-2 Inhibitor VI (5- Phenyl-2-ureido)thiophene-3-carboxamide, IKK-2 Inhibitor VIII ACHP 2-Amino-6-(2- (cyclopropylmethoxy)-6-hydroxyphenyl)-4-(4-piperidinyl)-3-pyridinecarbonitrile, TPCA-1, and BI605906. (i) when the RIPK1 inhibitor is a small molecule, the RIPK1 inhibitor is selected from GSK2982772, necrostatin-1 (5-(1H-indo1-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone, 5-(indoi-3-ylmethyl)-3-methyl-2-thio-hydantoin) and necrostatin-1 stable (5-((7-chloro-1 H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 5-((7-chloro-1H-indo1-3-yl)methyl)-3-methylimidazolidine-2,4-dione); or (ii) when the IKK/NFxB signaling inhibitor is a small molecule, the IKK/NFxB signaling inhibitor is selected from SPC839, Anilino-Pyrimidine Derivative, MLN120B or PS1145, BMS- 34554 1*, IKK inhibitor III, SC- 514*, Amino-imidazolecarboxamide derivative, Ureudothiophenecarboxamide derivatives, Diarylpybidine derivative, Pyridooxazinone derivative, Indolecarboxamide derivative, Benzoimidazole carboxamide derivative, Pyrazolo[4,3-c]quinoline derivative, Imidazolylquinoline-carbxaldehyde semicarbazide derivative, Pyridyl Cyanoguanidine derivate, IkB Kinase Inhibitor Peptide, IKK-2 Inhibitor IV [5-(p- Fluorophenyl)-2-ureido]thiophene-3-carboxamide, IKK Inhibitor II, Wedelolactone, IKK Inhibitor VII, IKK-2 Inhibitor V N-(3,5-Bis- trifluoromethylphenyl)-5-chloro-2-hydroxybenzamide IMD-0354, IKK-2 Inhibitor VI (5- Phenyl-2-ureido)thiophene-3-carboxamide, IKK-2 Inhibitor VIII ACHP 2-Amino-6-(2- (cyclopropylmethoxy)-6-hydroxyphenyl)-4-(4-piperidinyl)-3-pyridinecarbonitrile, TPCA-1, and BI605906. <EOS>